Minerva Neurosciences Inc

4MNA

Company Profile

  • Business description

    Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.

  • Contact

    1500 District Avenue
    BurlingtonMA01803
    USA

    T: +1 617 600-7373

    E: [email protected]

    https://www.minervaneurosciences.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    8

Stocks News & Analysis

stocks

Overvalued ASX mining giant

Solid start to 2026 but shares overvalued.
stocks

Going into earnings, is Microsoft stock a buy, a sell, or fairly valued?

With recent structural changes and strong Azure performance, here’s what we think of Microsoft stock.
stocks

Tesla earnings: Shares fall as market focuses on uncertainty in near term

Are shares overpriced despite the fall?

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,317.2026.50-0.28%
CAC 408,225.7818.910.23%
DAX 4024,207.7956.660.23%
Dow JONES (US)46,734.61144.200.31%
FTSE 1009,578.5763.570.67%
HKSE26,143.29175.310.68%
NASDAQ22,941.80201.400.89%
Nikkei 22549,299.65658.041.35%
NZX 50 Index13,391.5914.490.11%
S&P 5006,738.4439.040.58%
S&P/ASX 2009,019.0025.20-0.28%
SSE Composite Index3,948.0025.590.65%

Market Movers